VitriVax raises $17.25M Series B financing to advance vaccine formulation platform
ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ spinout VitriVax has raised $17.25 million in Series B financing to accelerate development of its Stablevaxâ„¢ platform, which eliminates the need for cold storage in vaccines. The funding will support preclinical and clinical advancement of single-dose, thermostable vaccines aimed at improving global immunization access.
The University of Colorado Connection
VitriVax is a biotechnology company working to eliminate barriers to global vaccination, and has developed a novel stabilization and delivery platform for vaccines and therapeutics based on research in the laboratories of (ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ Molecular, Cellular & Developmental Biology) and Ìýat ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ (ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ Chemical and Biological Engineering).
The Newsroom
For marketing and communication inquiries or news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at ÃÛÌÒ´«Ã½Æƽâ°æÏÂÔØ.
For media inquiries, please visit .